Clinical Trial Update: A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms [Phase 1]

View source ↗

Summary

This is a Phase I trial update evaluating continuous infusion of UCN-01 in patients with refractory neoplasms, with the study status indicated as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Lymphoma
• Prostate Cancer

Drugs mentioned

• UCN-01 (7-hydroxystaurosporine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer, Lymphoma | Phase 1 | Status: COMPLETED